DUESSELDORF (dpa-AFX) - Gerresheimer AG (GRRMF.PK), a German maker of
packaging products for medication and drug delivery devices, Monday announced
that it has entered into a partnership with the US digital health company RxCap
and acquired a minority stake.

Under the deal terms, Gerresheimer's unit Centor will receive the exclusive
distribution rights for pharmacies in the U.S. for adherence solutions by RxCap.
The deal consists of connected prescription vial closure devices and
complementary cloud-based software.

The RxCap solution is now available for U.S. pharmacies and can be ordered
directly from Centor.

Centor will offer RxCap's suite of connected prescription vial closure devices
and complementary cloud-based software to pharmacies. These solutions can easily
be integrated with existing enterprise workflows to manage patient needs
effectively.

The company noted that the partnership will enable pharmacies to quickly launch
adherence solutions that can support patient's health journey more effectively,
with minimal additional investments in their workflow, and create new revenue
streams.

As part of the partnership, Gerresheimer has acquired a minority stake in RxCap
in addition to the exclusive distribution rights for pharmacies in the United
States. Gerresheimer will also appoint a representative to RxCap's Board of
Directors.

Tony Haba, Senior Vice President North America at Gerresheimer, said, 'The
adherence solutions from RxCap is an ideal complement to the Centor prescription
vials. Solutions for digital therapy support are a future growth market for
Gerresheimer. That is why we are increasingly offering our customers innovative
solutions consisting of connected primary packaging and digital monitoring
platforms.'



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX